Highly galactosylated anti-TNF-α antibodies and uses thereof
US10174110B2 · kind B2 · utility
3Cited by
70References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 13, 2014 |
| Grant date | Jan 8, 2019 |
| Priority date | — |
| Expiry date | May 1, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In one aspect, the disclosure relates to highly galactosylated anti-TNF-alpha antibodies and compositions thereof. In one aspect, the disclosure relates to populations of anti-TNF-alpha antibodies with a high level of galactosylation, and compositions thereof. In one aspect, the disclosure relates to methods of production and use of highly galactosylated anti-TNF-alpha antibodies and populations of anti-TNF-alpha antibodies with a high level of galactosylation. In some embodiments, the anti-TNF-alpha antibody is adalimumab.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.